Duke Rohlen is the CEO of Cordis-X – an independent innovation hub designed to provide a pipeline of new products for Cordis. 

Mr. Rohlen also serves as CEO and Managing Director of Ajax Health, a team of entrepreneurs, business strategists, and investors that identify, invest in, and scale disruptive healthcare technologies. To date, Ajax-developed technologies have generated over $750 million in annual revenue for their acquirers and have been used to treat over one million patients. 

Over the past 15 years, Mr. Rohlen has built and sold four medical device companies with a combined enterprise value of over $1.7 billion. In addition to his roles at Cordis-X and Ajax, Mr. Rohlen currently serves on the boards of directors of Ablacon (Executive Chairman), Serpex Medical (Executive Chairman), XII Medical (Executive Chairman), Foresight Mental Health (Director), and the United States Ski and Snowboard Association (Trustee). Prior to Ajax, Mr. Rohlen co-founded and served as Chairman and CEO of EPIX Therapeutics (acquired by Medtronic), co-founder and CEO of Spirox (acquired by Entellus), and co-founder and CEO of CV Ingenuity (acquired by Covidien). Prior to CV Ingenuity, he also served in a variety of roles at FoxHollow Technologies before being named President. In that role, he led the sale of the company to ev3 (now Medtronic). Mr. Rohlen received an M.B.A. from Harvard Business School and a B.A. from Stanford University.